Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
PUMA BIOTECHNOLOGY, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Full financial results and management commentary provided in Exhibit 99.1
- Investor focus: revenue, profitability, cash position, and Nerlynx performance in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 product revenue $54.1M, up from $51.9M, signaling higher NERLYNX demand despite gross-to-net pressure
- Q3 net income $6.0M versus $8.8M, while R&D increased to $18.3M to support alisertib trials
- Cash, equivalents and marketable securities $108.5M, up from $97.5M, with current debt reduced to $0
- 2026 net income guidance raised to $20M-$22M from $17M-$20M
- Alisertib pipeline advancing with ALISCA-Lung2 initiated and Phase III regulatory discussions targeted for H1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PUMA BIOTECHNOLOGY, INC. 8-K filings
Get the next PBYI 8-K as it lands
Follow PBYI for push alerts, or ask the research agent what this filing means.